drugset
drugset / Trial / NCT06441097

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

NCT06441097 ↗

Phase 2 Not yet recruiting 152 enrolled Ruijin Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Timeline

Start
2024-12-31
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral
Subject Decitabine Small molecule 10 mg/m2 Intravenous
Subject Lenalidomide Other / unclassified 25 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Polatuzumab Vedotin Other / unclassified 1.8 mg/kg Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma